Xiong 2013.

Methods	Study design: Randomised clinical trial Study duration: January 2009 to May 2011 Duration of follow‐up: Not reported Setting: Hospital
Participants	Inclusion criteria: Aged ≥ 60 years; diagnosed as HCC by pathology; unsuitable for resection or unwilling to accept surgery; Karnofsky score ≥ 60; life expectancy ≥ 3 months; no contraindications for TACE or HIFU; no extrahepatic metastasis; tumour volume ≤ 70% of whole liver volume Age (mean ± SD, range): TACE + RFA: 73.4 ± 4.5 years; TACE alone: 74.2 ± 5.6 years Male (n/total): TACE + RFA: 20/35; TACE alone: 21/35 Tumour diameter (mean ± SD): TACE + RFA: 6.3 ± 2.1 cm; TACE: 6.5 ± 2.0 cm Child‐Pugh Class (patients): Class A: TACE + RFA: 27; TACE: 28 Class B: TACE + RFA: 8; TACE: 7
Interventions	TACE + RFA group (n = 35): TACE: Chemotherapeutic drugs: 5‐fluorouracil, epirubicin, and mitomycin RFA: The interval between TACE and RFA was 1‐2 weeks. Ablation margin of 0.5‐1 cm TACE group (n = 35): Chemotherapeutic drugs: 5‐fluorouracil, epirubicin, and mitomycin
Outcomes	Serum level of AFP Tumour response, assessed at 6 weeks after treatment, measured by contrast‐enhanced CT or MRI
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.